216 related articles for article (PubMed ID: 30419834)
1. Clinical and genetic factors associated with increased risk of severe liver toxicity in a monocentric cohort of HIV positive patients receiving nevirapine-based antiretroviral therapy.
Giacomelli A; Riva A; Falvella FS; Oreni ML; Cattaneo D; Cheli S; Renisi G; Di Cristo V; Lupo A; Clementi E; Rusconi S; Galli M; Ridolfo AL
BMC Infect Dis; 2018 Nov; 18(1):556. PubMed ID: 30419834
[TBL] [Abstract][Full Text] [Related]
2. Analysis of severe hepatic events associated with nevirapine-containing regimens: CD4+ T-cell count and gender in hepatitis C seropositive and seronegative patients.
Torti C; Costarelli S; De Silvestri A; Quiros-Roldan E; Lapadula G; Cologni G; Paraninfo G; Castelnuovo F; Puoti M; Carosi G;
Drug Saf; 2007; 30(12):1161-9. PubMed ID: 18035868
[TBL] [Abstract][Full Text] [Related]
3. Risk and determinants of developing severe liver toxicity during therapy with nevirapine-and efavirenz-containing regimens in HIV-infected patients.
Ena J; Amador C; Benito C; Fenoll V; Pasquau F
Int J STD AIDS; 2003 Nov; 14(11):776-81. PubMed ID: 14624743
[TBL] [Abstract][Full Text] [Related]
4. Maternal hepatotoxicity with nevirapine as part of combination antiretroviral therapy in pregnancy.
Lyons F; Hopkins S; Kelleher B; McGeary A; Sheehan G; Geoghegan J; Bergin C; Mulcahy FM; McCormick PA
HIV Med; 2006 May; 7(4):255-60. PubMed ID: 16630038
[TBL] [Abstract][Full Text] [Related]
5. Nevirapine-induced hepatotoxicity and pharmacogenetics: a retrospective study in a population from Mozambique.
Ciccacci C; Borgiani P; Ceffa S; Sirianni E; Marazzi MC; Altan AM; Paturzo G; Bramanti P; Novelli G; Palombi L
Pharmacogenomics; 2010 Jan; 11(1):23-31. PubMed ID: 20017669
[TBL] [Abstract][Full Text] [Related]
6. The impact of HBV or HCV infection in a cohort of HIV-infected pregnant women receiving a nevirapine-based antiretroviral regimen in Malawi.
Andreotti M; Pirillo MF; Liotta G; Jere H; Maulidi M; Sagno JB; Luhanga R; Amici R; Mancini MG; Gennaro E; Marazzi MC; Vella S; Giuliano M; Palombi L; Mancinelli S
BMC Infect Dis; 2014 Apr; 14():180. PubMed ID: 24708626
[TBL] [Abstract][Full Text] [Related]
7. Hcv coinfection, an important risk factor for hepatotoxicity in pregnant women starting antiretroviral therapy.
Snijdewind IJ; Smit C; Godfried MH; Nellen JF; de Wolf F; Boer K; van der Ende ME
J Infect; 2012 Apr; 64(4):409-16. PubMed ID: 22227465
[TBL] [Abstract][Full Text] [Related]
8. Risk of severe hepatotoxicity associated with antiretroviral therapy in the HIV-NAT Cohort, Thailand, 1996-2001.
Law WP; Dore GJ; Duncombe CJ; Mahanontharit A; Boyd MA; Ruxrungtham K; Lange JM; Phanuphak P; Cooper DA
AIDS; 2003 Oct; 17(15):2191-9. PubMed ID: 14523276
[TBL] [Abstract][Full Text] [Related]
9. Incidence of liver injury after beginning antiretroviral therapy with efavirenz or nevirapine.
Martín-Carbonero L; Núñez M; González-Lahoz J; Soriano V
HIV Clin Trials; 2003; 4(2):115-20. PubMed ID: 12671779
[TBL] [Abstract][Full Text] [Related]
10. Nevirapine-associated hepatotoxicity was not predicted by CD4 count ≥250 cells/μL among women in Zambia, Thailand and Kenya.
Peters PJ; Stringer J; McConnell MS; Kiarie J; Ratanasuwan W; Intalapaporn P; Potter D; Mutsotso W; Zulu I; Borkowf CB; Bolu O; Brooks JT; Weidle PJ
HIV Med; 2010 Nov; 11(10):650-60. PubMed ID: 20659176
[TBL] [Abstract][Full Text] [Related]
11. Influence of liver fibrosis on highly active antiretroviral therapy-associated hepatotoxicity in patients with HIV and hepatitis C virus coinfection.
Aranzabal L; Casado JL; Moya J; Quereda C; Diz S; Moreno A; Moreno L; Antela A; Perez-Elias MJ; Dronda F; Marín A; Hernandez-Ranz F; Moreno A; Moreno S
Clin Infect Dis; 2005 Feb; 40(4):588-93. PubMed ID: 15712082
[TBL] [Abstract][Full Text] [Related]
12. Liver toxicity of initial antiretroviral drug regimens including two nucleoside analogs plus one non-nucleoside analog or one ritonavir-boosted protease inhibitor in HIV/HCV-coinfected patients.
Macías J; Neukam K; Mallolas J; López-Cortés LF; Cartón JA; Domingo P; Moreno S; Iribarren JA; Clotet B; Crespo M; de Los Santos I; Ortega E; Knobel H; Jiménez-Expósito MJ; Pineda JA;
HIV Clin Trials; 2012; 13(2):61-9. PubMed ID: 22510353
[TBL] [Abstract][Full Text] [Related]
13. Hepatotoxicity in HIV-1-infected patients receiving nevirapine-containing antiretroviral therapy.
Martínez E; Blanco JL; Arnaiz JA; Pérez-Cuevas JB; Mocroft A; Cruceta A; Marcos MA; Milinkovic A; García-Viejo MA; Mallolas J; Carné X; Phillips A; Gatell JM
AIDS; 2001 Jul; 15(10):1261-8. PubMed ID: 11426070
[TBL] [Abstract][Full Text] [Related]
14. Incidence and risk factors of skin rashes and hepatotoxicity in HIV-infected patients receiving nevirapine-containing combination antiretroviral therapy in Taiwan.
Tseng YT; Yang CJ; Chang SY; Lin SW; Tsai MS; Liu WC; Wu PY; Su YC; Luo YZ; Yang SP; Hung CC; Chang SC
Int J Infect Dis; 2014 Dec; 29():12-7. PubMed ID: 25312984
[TBL] [Abstract][Full Text] [Related]
15. Short communication: interactions between nevirapine plasma levels, chronic hepatitis C, and the development of liver toxicity in HIV-infected patients.
Núñez M; González-Requena D; González-Lahoz J; Soriano V
AIDS Res Hum Retroviruses; 2003 Mar; 19(3):187-8. PubMed ID: 12689410
[TBL] [Abstract][Full Text] [Related]
16. Occurrence of CYP2B6 516G>T polymorphism in patients with ARV-associated hepatotoxicity.
Singh H; Lata S; Dhole TN; Gangakhedkar RR
Mol Genet Genomic Med; 2019 Apr; 7(4):e00598. PubMed ID: 30864294
[TBL] [Abstract][Full Text] [Related]
17. Incidence of and risk factors for severe hepatotoxicity of nelfinavir-containing regimens among HIV-infected patients with chronic hepatitis C.
Mira JA; Macías J; Girón-González JA; Merino D; González-Serrano M; Jiménez-Mejías ME; Caballero-Granado FJ; Torre-Cisneros J; Terrón A; Becker MI; Gómez-Mateos J; Arizcorreta-Yarza A; Pineda JA;
J Antimicrob Chemother; 2006 Jul; 58(1):140-6. PubMed ID: 16720565
[TBL] [Abstract][Full Text] [Related]
18. Discontinuation of nevirapine because of hypersensitivity reactions in patients with prior treatment experience, compared with treatment-naive patients: the ATHENA cohort study.
Wit FW; Kesselring AM; Gras L; Richter C; van der Ende ME; Brinkman K; Lange JM; de Wolf F; Reiss P
Clin Infect Dis; 2008 Mar; 46(6):933-40. PubMed ID: 18271750
[TBL] [Abstract][Full Text] [Related]
19. Increased risk of hepatotoxicity in HIV-infected pregnant women receiving antiretroviral therapy independent of nevirapine exposure.
Ouyang DW; Shapiro DE; Lu M; Brogly SB; French AL; Leighty RM; Thompson B; Tuomala RE; Hershow RC
AIDS; 2009 Nov; 23(18):2425-30. PubMed ID: 19617813
[TBL] [Abstract][Full Text] [Related]
20. Hepatotoxicity of antiretroviral drugs is reduced after successful treatment of chronic hepatitis C in HIV-infected patients.
Labarga P; Soriano V; Vispo ME; Pinilla J; Martin-Carbonero L; Castellares C; Casado R; Maida I; Garcia-Gasco P; Barreiro P
J Infect Dis; 2007 Sep; 196(5):670-6. PubMed ID: 17674307
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]